Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer

Table 3 Results of Cox univariate analyses

Characteristic	Progression-free survival			Overall survival
	Hazard ratio	95%CI	P-value	Hazard ratio	95%CI	P-value
Age, yr
Continuous	0.999	0.984; 1.016	0.98	1.002	0.986; 1.018	0.81
Gender
Female	1			1
Male	0.827	0.597; 1.145	0.25	0.898	0.645; 1.251	0.53
Who performance status
0	1			1
1	1.569	0.926; 2.660	0.09	2.039	0.143; 3.639	0.02
2	2.827	0.473; 5.428	0.002	5.335	2.647; 10.75	< 0.01
Primary location
Right colon	1			1
Left colon	0.979	0.660; 1.454	0.92	0.945	0.634; 1.410	0.78
Rectum	1.018	0.671; 1.545	0.93	1.029	0.673; 1.572	0.90
Initial cancer status
Synchronous	1			1
Metachronous	0.815	0.572; 1.162	0.26	0.839	0.583; 1.208	0.34
No. of metastastatic sites
1	1			1
2	1.225	0.823; 1.823	0.32	1.241	0.824; 1.870	0.30
≥ 3	1.361	0.883; 2.098	0.16	1.490	0.954; 2.326	0.08
Surgery of primary
No	1			1
Yes	0.789	0.564; 1.104	0.17	0.799	0.568; 1.124	0.20
Surgery of metastases
No	1			1
Yes	0.592	0.388; 0.903	0.01	0.725	0.475; 1.107	0.13
Line of therapy
Second	1			1
Third	1.055	0.615; 1.812	0.85	1.126	0.646; 1.962	0.68
More	1.728	1.060; 2.816	0.03	1.531	0.931; 2.517	0.09
Treatment
FOLFIRI	1			1
FOLFIRI3 + Bevacizumab	1.055	0.615; 1.812	0.85	0.791	0.471; 1.329	0.38
FOLFIRI3 + Aflibercept	1.728	1.060; 2.816	0.03	0.470	0.255; 0.866	0.02
Irinotecan chemotherapy-naive
	1			1
No vs yes	0.731	0.474; 1.127	0.15	0.838	0.539; 1.303	0.43
RAS/BRAF mutation status
Not mutated	1			1
Mutated	0.910	0.641; 1.293	0.60	0.986	0.690; 1.408	0.94